Paper Details

  1. Home
  2. Paper Details

Intraocular pressure-lowering effect of omidenepag isopropyl in latanoprost non-/low-responder patients with primary open-angle glaucoma or ocular hypertension: the FUJI study.

Author: AiharaMakoto, IwataAkihiro, KawataHisashi, LuFenghe, Odani-KawabataNoriko, RopoAuli, ShamsNaveed

Clinical Trial, Phase IIIA Phase III trial is a trial that further rigorously verifies the efficacy and safety of a new drug or treatment, whose efficacy and safety have been confirmed in a Phase II trial, in a large number of patients, and evaluates whether it is superior to existing treatments.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.

Overview

Omidenepag isopropyl (OMDI) is a selective prostanoid EP2 receptor agonist used to lower intraocular pressure (IOP) in glaucoma and ocular hypertension (OHT) patients. This study evaluated the efficacy and safety of OMDI ophthalmic solution 0.002% in patients with primary open-angle glaucoma or OHT who were non-/low responders to latanoprost.
Paper Details　
Original Abstract of the Article :
Omidenepag isopropyl (OMDI) is the prodrug of omidenepag, a selective, non-prostaglandin, prostanoid EP2 receptor agonist, which has been shown to lower intraocular pressure (IOP) in patients with glaucoma and ocular hypertension (OHT). This study evaluated the efficacy and safety of OMDI ophthalmic...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1007/s10384-020-00748-x

データ提供：米国国立医学図書館（NLM）

Omidenepag Isopropyl: A Camel's Journey to Lowering Intraocular Pressure

Primary open-angle glaucoma (POAG) and ocular hypertension (OHT), conditions affecting the eye's pressure, can lead to vision loss if left untreated. This study explores the efficacy and safety of omidenepag isopropyl (OMDI), a selective prostanoid EP2 receptor agonist, in patients with POAG or OHT who were non- or low-responders to latanoprost.

A New Oasis in the Desert: OMDI Shows Promise in Lowering IOP

OMDI demonstrated a significant IOP-lowering effect in patients with POAG or OHT who had not responded well to latanoprost. The study findings provide valuable insights into the potential of OMDI as a viable treatment option for patients who require alternative therapies to manage their IOP. It highlights the importance of personalized medicine, ensuring that patients receive the most effective treatment for their individual needs.

Navigating the Eye's Desert: A Camel's Guide to Vision Health

Maintaining healthy eye pressure is crucial for preserving vision. This study underscores the potential benefits of OMDI, offering a new oasis in the desert of treatment options for POAG and OHT. By working closely with healthcare professionals, individuals can navigate the complexities of managing IOP, ensuring the best possible outcomes for their eye health. It's important to remember that proactive care can help preserve vision and maintain a healthy lifestyle, much like a camel traversing a desert landscape with careful navigation and a focus on hydration.

Dr. Camel's Conclusion

The desert of eye health can be vast and challenging, but with the right guidance and innovative treatments, we can protect our vision. This study highlights the potential of OMDI as a valuable tool for managing IOP in patients who have not responded well to other therapies. It reminds us that even in the face of complex eye conditions, there can be oases of hope, providing opportunities to maintain healthy vision and a good quality of life.
Date :
  1. Date Completed 2021-05-21
  2. Date Revised 2021-05-21
Further Info :

Pubmed ID

32572719

DOI: Digital Object Identifier

10.1007/s10384-020-00748-x

Related Literature

Article Analysis
・Effects of latanoprost ophthalmic
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.